Genentech exec appointments
Executive Summary
Hal Barron, MD, will head Genentech's newly formed development organization combining the medical affairs and developmental sciences departments. He was previously VP-medical affairs, and will continue to report to Chief Medical Officer Susan Hellmann, MD. Patrick Yang, PhD, joins Genentech from Merck as VP-South San Francisco manufacturing and engineering, reporting to Senior VP-Product Operations David Ebersman. At Merck, Yang was VP-Asia/Pacific Manufacturing Operations. Both positions are newly created...
You may also be interested in...
Genentech CFO
Genentech CFO Lou Lavigne will retire in March 2005 after serving as a Genentech finance exec for over 22 years. He first served as controller and was promoted to CFO in 1988. In his retirement, Lavigne intends to serve on the boards of other companies. Senior VP-Product Operations David Ebersman will replace Lavigne as CFO. Pat Yang, PhD, who serves as VP-South San Francisco manufacturing & engineering, will be promoted to senior VP-product operations. Yang joined the company from Merck in late 2003 (1"The Pink Sheet" Jan. 19, 2004, In Brief)...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.